نتائج البحث - Torben Plesner

تنقيح النتائج
  1. 1
    Daratumumab for the Treatment of Multiple Myeloma

    Daratumumab for the Treatment of Multiple Myeloma حسب Torben Plesner, Jakub Krejcik

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR

    Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR حسب Torben Plesner, Niels Behrendt, Michael Ploug

    منشور في 1997
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells

    Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells حسب Thomas Levin Andersen, Kent Søe, Teis Esben Søndergaard, Torben Plesner, Jean‐Marie Delaissé

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation

    Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation حسب Patrice Boissy, Thomas Levin Andersen, Basem M. Abdallah, Moustapha Kassem, Torben Plesner, Jean‐Marie Delaissé

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria

    The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria حسب Michael Ploug, Torben Plesner, Ebbe Rønne, Vincent Ellis, G Hoyer-Hansen, NE Hansen, Keld Danø

    منشور في 1992
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

    Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells حسب Therese Standal, Carina Seidel, Øyvind Hjertner, Torben Plesner, Ralph D. Sanderson, Anders Waage, Magne Börset, Anders Sundan

    منشور في 2002
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils

    The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neut... حسب Torben Plesner, Michael Ploug, Vincent Ellis, Ebbe Rønne, Gunilla Høyer‐Hansen, M Wittrup, TL Pedersen, T Tscherning, Keld Danø, NE Hansen

    منشور في 1994
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone

    A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone حسب Thomas Levin Andersen, Teis Esben Søndergaard, Katarzyna Skórzyńska-Dziduszko, Frederik Dagnæs‐Hansen, Trine Lindhardt Plesner, Ellen‐Margrethe Hauge, Torben Plesner, Jean‐Marie Delaissé

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia

    A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia حسب Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch, Inge Helleberg Rasmussen, Ove Juul Nielsen, Lars Kjeldsen, Herdis Larsen, Torben Mourits‐Andersen, Torben Plesner, Dorthe Rønnov‐Jessen, Hanne Vestergaard, Tobias Wirenfeldt Klausen, Claudia Schöllkopf

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

    Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma حسب Niels W.C.J. van de Donk, Philippe Moreau, Torben Plesner, Antonio Palumbo, Francesca Gay, Jacob P. Laubach, Fabio Malavasi, Hervé Avet‐Loiseau, María‐Victoria Mateos, Pieter Sonneveld, Henk M. Lokhorst, Paul G. Richardson

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma حسب Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W.C.J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    The Danish National Multiple Myeloma Registry

    The Danish National Multiple Myeloma Registry حسب Peter Gimsing, Morten Orebo Holmström, Tobias Wirenfelt Klausen, Niels Frost Andersen, Henrik Gregersen, Robert Schou Pedersen, Torben Plesner, Per Trøllund Pedersen, Mikael Frederiksen, Ulf Christian Frølund, Carsten Helleberg, Annette Juul Vangsted, Peter de Nully Brown, Niels Abildgaard

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma حسب Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

    Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura حسب Peter Brændstrup, Ole Weis Bjerrum, Ove Juul Nielsen, Bjarne Anker Jensen, Nielsaage Tøffner Clausen, Per Boye Hansen, Ivan Andersen, Kai Gjerløff Schmidt, Torben M. Andersen, Niels Anker Peterslund, Henrik Birgens, Torben Plesner, Bjarne Bach Pedersen, Hans Carl Hasselbalch

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

    Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) حسب Nizar J. Bahlis, Rachid Baz, Simon J. Harrison, Hang Quach, Shir‐Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A. Ross, Orlando F. Bueno, Jonathan L. Kaufman

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference حسب Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi, A. Kate Sasser

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

    Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia حسب Sif Gudbrandsdottir, Henrik Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov‐Jessen, Hans Carl Hasselbalch

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma حسب Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma حسب Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesús F. San Miguel

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma حسب Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick J. Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen K. Miller, Eunpi Cho, Fredrik Schjesvold

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: